Medical Marijuana, Inc. Portfolio Company Kannalife, Inc. Publishes New Research on CBD and Chemotherapy-Induced Peripheral Neuropathy

 Medical Marijuana, Inc., the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that the Company’s portfolio company Kannalife, Inc., a biopharmaceutical company leading innovation in research, development and discovery of natural and novel biomimetic cannabinoid therapeutic agents, published its research findings around Chemotherapy-Induced Peripheral Neuropathy (CIPN) in the Journal of Molecular Neuroscience.

According to Market Study Report, LLC, the global market for the treatment of symptoms associated with CIPN is expected to hit $1.88 billion by 2024. Kannalife is targeting clinical trials for KLS-13019, its proprietary CBD-like molecule, as a therapeutic for CIPN to begin in Q2 2020.

“CIPN affects the lives of up to 30 to 40 percent of patients undergoing chemotherapy and we are proud to support Kannalife in actively researching to find an alternative treatment option for these patients,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus.

The paper, titled “Knockdown siRNA Targeting the Mitochondrial Sodium-Calcium Exchanger-1 Inhibits the Protective Effects of Two Cannabinoids Against Acute Paclitaxel Toxicity,” compares cannabidiol (CBD) and Kannalife’s proprietary CBD-like molecule KLS-13019 and its effects on the mitochondrial sodium-calcium exchanger-1. The paper details the protective action of both molecules against this exchanger, known to increase calcium levels in patients taking the chemotherapy drug paclitaxel.

Kannalife worked on this research under a grant from the National Institute on Drug Abuse it received in 2017. The grant allows for research into the development of KLS-13019 for chemotherapy-induced peripheral neuropathy and drug dependence. According to the grant, Kannalife is researching significant advancements in identifying the specific mechanisms that induce CIPN, application of that knowledge to design novel treatment strategies for neuropathic pain and applying those treatment strategies to reduce or replace prescription opioid use and decrease prescription opioid abuse.

“At Kannalife, we continue to push the boundaries on scientific discovery in developing treatment alternatives for diseases like CIPN with unmet medical needs,” said Kannalife CCO Thoma Kikis. “We are extremely excited with the potential of KLS-13019 and look forward to the future discoveries by our skilled team of scientists.”